Skip to Content
Merck
CN

4202001

PRONOVA® SLG 20

sodium alginate solution, Mw 75-150 kDa, guluronate monomer units ≥60 %

Synonym(s):

Sterile sodium alginate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

NACRES:
NA.25
UNSPSC Code:
12352201

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

PRONOVA® SLG 20, sodium alginate solution, Mw 75-150 kDa, guluronate monomer units ≥60 %

sterility

sterile (Total viable count (CFU/g))

form

powder

mol wt

Mw 75-150 kDa

composition

guluronate monomer units, ≥60%
G/M ratio, ≥1.5

pH

5.5-8.5 (20 °C, 1% in water)

viscosity

20-99 mPa.s, 1 % in water(20 °C)

Quality Level

100

Application

Examples of Pronova Alginates applications include: encapsulation of living cells and therapeutic proteins for cell therapy medications, cryoprotectant, bone putty binder for tissue engineering, 3D bioprinting, foams and cell tissue scaffolds, hydrogels, advanced drug delivery and implants, wound management, and medical devices.

Disclaimer

NOT FOR USE IN HUMANS

General description

SLG-20 is made from an alginate where over 60% of the monomer units are guluronate and is a highly purified and well-characterized sodium alginate. The molecular weight for PRONOVA SLG-20 is in the 75000 – 220000 g/mol range. The ultra low levels of endotoxins, proteins and product sterility allows for a big variety of in vitro and in vivo applications.

Legal Information

Product of Dupont Nutrition USA, Inc.
PRONOVA is a registered trademark of International N&H USA, Inc.

wgk

WGK 1

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Rational Design of ECMs Toward Cancer Immunotherapy

Engineered ECMs enhance immune therapy in cancer treatment by supporting cells and tissues and modulating immune response. They improve immune cell maturation, expansion, and regulation through biomaterial manipulation, acting as frameworks or carriers for enhanced tumor immunotherapy.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service